Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to ...

While Novo Nordisk and Pfizer intensify their plays, Lilly’s early lead in GLP-1 treatments has put it in a category all its ...

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Eli Lilly hit a $1 trillion valuation, driven by demand for Zepbound and Mounjaro. The first health-care firm ever to join ...

Eli Lilly became the first healthcare company to hit a $1 trillion valuation (briefly on Nov. 21) MONDAY, Nov. 24, 2025 ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC.

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across ...

Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group of companies ...